If you’ve been hearing about Ozempic everywhere lately, you’re not alone. I’ve spent weeks diving into the research to find out exactly how many Americans are using this medication.
About 1 in 8 American adults (12%) have ever used Ozempic or another GLP-1 medication, with approximately 6% currently taking one. This translates to roughly 15-16 million current users across the United States.
The numbers have grown dramatically. According to KFF polling data, GLP-1 usage has more than doubled since early 2024, making these medications one of the fastest-growing drug categories in American history.
In this comprehensive guide, I’ll break down the latest statistics on Ozempic usage in America, including demographics, costs, side effects, and what the research shows about who’s taking these medications and why.
ContentsTable of Contents
- 1Ozempic and GLP-1 Usage: Key Statistics at a Glance→
- 2How Many Americans Currently Take Ozempic?→
- 3Current vs. Ever Used→
- 4GLP-1 Prescription Trends: How Usage Has Grown→
- 5Who Uses Ozempic? Demographics Breakdown→
- 6Usage by Age Group→
- 7Usage by Ethnicity→
- 8Diabetes Treatment vs Weight Loss: Why Americans Use Ozempic→
- 9Usage Among Specific Conditions→
- 10Ozempic Market Growth and Future Projections→
- 11Market Size and Projections→
- 12Ozempic Cost and Affordability Statistics→
- 13US List Prices→
- 14Insurance Coverage Breakdown→
- 15International Price Comparison→
- 16Compounded Semaglutide→
- 17Ozempic vs Other GLP-1 Medications: Popularity Comparison→
- 18Prescription Rankings→
- 19Effectiveness Comparison→
- 20Side Effects and Discontinuation Rates→
- 21Discontinuation Statistics→
- 22Side Effect Rates→
- 23Public Awareness and Opinion→
- 24Medicare Coverage Opinion→
- 25Impact on Health and Lifestyle→
- 26Context: Obesity and Diabetes in America→
- 27Frequently Asked Questions→
- 28How many people are on Ozempic in the USA?→
- 29How many people are on Ozempic in 2025?→
- 30How many Americans are on GLP-1 medications?→
- 31What percentage of people feel sick on Ozempic?→
- 32Are people on Ozempic for life?→
- 33How many people are taking Ozempic for weight loss?→
- 34The Bottom Line on Ozempic Usage in America→
Ozempic and GLP-1 Usage: Key Statistics at a Glance
Before we dive into the details, here are the most important numbers you should know about Ozempic and GLP-1 usage in America.
Key Statistics Summary:
- 12% of American adults have ever used a GLP-1 medication
- 6% are currently taking a GLP-1 drug
- 2% were prescribed Ozempic specifically in 2024
- 15.5 million Americans have tried GLP-1 drugs
- 30 million users projected by 2030
| Statistic | Number | Source |
|---|---|---|
| Ever used GLP-1 | 12% of adults | KFF May 2024 |
| Currently taking GLP-1 | 6% of adults | KFF May 2024 |
| Prescribed Ozempic (2024) | 2% of adults | NutritionNC 2025 |
| GLP-1 share of all prescriptions | 5.4% | MIT Technology Review |
| Projected users by 2030 | 30 million (9%) | Industry projections |
How Many Americans Currently Take Ozempic?
Approximately 6% of American adults are currently taking a GLP-1 medication like Ozempic, according to the KFF Health Tracking Poll from May 2024. This represents a significant portion of the adult population.
When we look specifically at Ozempic, about 2% of American adults were prescribed this particular medication in 2024. This makes Ozempic the most prescribed GLP-1 drug in the United States.
The total number of Americans who have ever tried a GLP-1 medication is even higher. According to research, approximately 15.5 million Americans have used drugs like Ozempic, Wegovy, or Mounjaro at some point.
Current vs. Ever Used
There’s an important distinction between current users and those who have tried these medications. While 12% of adults have ever used a GLP-1, only 6% are actively taking one now.
This gap suggests that half of people who try GLP-1 medications eventually stop taking them. I’ll explore the reasons for discontinuation later in this article.
According to a Gallup poll from October 2026, GLP-1 usage has climbed to 12.4% of respondents, up from 5.8% in February 2024. This represents more than a doubling of users in less than a year.
GLP-1 Prescription Trends: How Usage Has Grown
The growth of Ozempic and other GLP-1 medications has been nothing short of remarkable. Based on my research into prescription data, usage has increased 40-fold between 2017 and 2021 alone.
Here’s how the numbers have evolved over time:
- 2019: Approximately 569 Ozempic users tracked in studies
- 2020: Jumped to 7,667 users
- 2021: Grew to over 13,000 users
- 2022: Reached approximately 23,000 users
- 2026: Millions of Americans now using GLP-1s
GLP-1 medications now account for 5.4% of all American adult prescriptions as of September 2024. This is up from 3.5% in 2023, showing continued rapid growth.
The trajectory suggests these medications may become even more common. Industry analysts project that 30 million Americans, or 9% of the population, could be using GLP-1 drugs by 2030.
Who Uses Ozempic? Demographics Breakdown
Not everyone uses Ozempic at the same rate. The data reveals significant variations across different age groups and ethnic backgrounds.
Usage by Age Group
Adults aged 50-64 have the highest rate of GLP-1 usage at 19%. This makes sense given that type 2 diabetes and obesity rates increase with age.
| Age Group | Ever Used GLP-1 | For Chronic Condition | For Weight Loss |
|---|---|---|---|
| 18-29 | 10% | Not specified | 7% |
| 30-49 | 13% | 3% | 6% |
| 50-64 | 19% | 9% | 5% |
| 65+ | 9% | 6% | 1% |
Younger adults (18-29) have the highest rate of using GLP-1s specifically for weight loss at 7%. This suggests different motivations across age groups.
Adults 65 and older show the lowest overall usage at just 9%. This may be partly due to Medicare coverage limitations, which typically don’t cover these drugs for weight loss purposes.
Usage by Ethnicity
Black adults have the highest rate of GLP-1 usage at 18%, followed by Hispanic adults at 13%, and White adults at 10%.
| Ethnicity | Ever Used GLP-1 |
|---|---|
| Black adults | 18% |
| Hispanic adults | 13% |
| White adults | 10% |
According to KFF data, these patterns align with higher rates of obesity and type 2 diabetes in Black and Hispanic communities. The medications may be helping address health disparities, though access and affordability remain concerns.
Diabetes Treatment vs Weight Loss: Why Americans Use Ozempic
Ozempic was originally approved for type 2 diabetes, but many Americans now use it for weight loss. The data shows an interesting split in usage purposes.
According to KFF polling, 62% of GLP-1 users took the medications to treat chronic conditions like diabetes or heart disease. However, 38% took them solely for weight loss.
Usage Purpose Breakdown:
- 39% use only for chronic condition treatment
- 38% use solely for weight loss
- 23% use for both weight loss and chronic condition
Usage Among Specific Conditions
The rate of GLP-1 usage varies significantly depending on health conditions:
- 43% of diabetics have used GLP-1 medications
- 26.5% of diagnosed diabetics currently use GLP-1 injectables (CDC data)
- 26% of heart disease patients have used GLP-1s
- 22% of those told they’re overweight/obese by a doctor have used GLP-1s
These numbers show that GLP-1 medications have become a mainstream treatment option for diabetes and are increasingly being prescribed for weight management.
Ozempic Market Growth and Future Projections
The financial data behind Ozempic reveals just how significant this medication has become. I was surprised by the scale of the market growth.
Ozempic and Wegovy (both made by Novo Nordisk and containing semaglutide) generated $26 billion in combined annual sales in 2024. This makes semaglutide one of the best-selling drugs in pharmaceutical history.
Market Size and Projections
| Metric | Current Value | Projection |
|---|---|---|
| GLP-1 market (weight loss) | $13.84 billion (2026) | $48.84 billion (2030) |
| Total GLP-1 market | $100+ billion (projected 2030) | $471 billion (2032 estimate) |
| Growth rate (CAGR) | 18.54% | Continuing strong |
North America accounts for 77.72% of global GLP-1 revenue, with the US representing 95.2% of that North American share. This means the American market dominates global sales.
The two major manufacturers control this market. Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) account for over 90% of all GLP-1 drugs sold worldwide.
Americans spent $39 billion on semaglutide products in 2023, making it the highest-spending drug category in the country.
Ozempic Cost and Affordability Statistics
Cost is one of the biggest barriers to Ozempic access. The prices in the United States are significantly higher than in other countries.
US List Prices
| Medication | Monthly Cost (US) |
|---|---|
| Ozempic | $936/month |
| Rybelsus (oral semaglutide) | $936/month |
| Mounjaro | $1,023/month |
| Wegovy | $1,349/month |
According to KFF research, 54% of GLP-1 users found it difficult to afford their medication. Even more concerning, 22% said it was “very difficult” to afford.
Even having insurance doesn’t solve the problem. Among insured GLP-1 users, 53% still reported difficulty affording the medication.
Insurance Coverage Breakdown
The data on insurance coverage reveals significant gaps:
- 57% of insured users had partial coverage
- 24% had full insurance coverage
- 19% paid entirely out of pocket
Less than 1% of Americans pay fully out of pocket for Ozempic, meaning most users rely on some form of insurance or assistance programs.
International Price Comparison
US prices are dramatically higher than in other developed countries. This disparity has fueled debate about drug pricing reform.
| Country | Ozempic Monthly Cost | Comparison to US |
|---|---|---|
| United States | $936 | Baseline |
| Japan | $169 | 82% less |
| United Kingdom | Under $100 | 89%+ less |
| France | Under $100 | 89%+ less |
| Australia | Under $100 | 89%+ less |
| Sweden | Under $100 | 89%+ less |
According to Health System Tracker data, US prices may be up to 10 times higher than in peer nations. This has led some Americans to seek medication from international pharmacies or turn to compounded alternatives.
Compounded Semaglutide
Approximately 2 million patients used compounded semaglutide between November 2023 and November 2024, according to the Outsourcing Facilities Association.
However, the FDA declared the semaglutide shortage ended in early 2026, which may limit future availability of compounded versions.
Disclaimer: Compounded medications are not FDA-approved and may not be available in all states.
Ozempic vs Other GLP-1 Medications: Popularity Comparison
While Ozempic gets most of the attention, it’s not the only GLP-1 medication available. Here’s how the different drugs compare in popularity.
Prescription Rankings
- Ozempic: Most prescribed – 2% of American adults in 2024
- Mounjaro: Second place – nearly 1% of adults
- Wegovy, Zepbound, Saxenda: Combined – around 0.7% of adults
Ozempic’s popularity may be attributed to its longer market presence and widespread marketing. It was approved by the FDA in 2017 for diabetes and has since gained recognition for weight loss effects.
Effectiveness Comparison
Different GLP-1 medications produce varying levels of weight loss:
| Medication | Average Weight Loss | A1C Reduction |
|---|---|---|
| Ozempic | 6-10% of body weight | 1.4-1.6% |
| Mounjaro | 12-17% of body weight | Comparable |
| Zepbound | Up to 21% of body weight | N/A (weight loss only) |
While newer medications may show greater weight loss, Ozempic remains popular due to its established safety record and broader insurance coverage.
Side Effects and Discontinuation Rates
Many people who start Ozempic eventually stop taking it. The discontinuation rates reveal important challenges with these medications.
Discontinuation Statistics
Studies show that 66-75% of people stop taking GLP-1 medications within one year. This high dropout rate is one of the most significant concerns with these treatments.
The reasons for stopping or delaying treatment include:
- Cost: 65% cite affordability as the top barrier
- Haven’t gotten around to it: 47%
- Side effect concerns: 39%
- Supply shortages: 28%
- Ineffectiveness: 16%
Interestingly, 42% of former users said they would likely resume treatment if cost and side effects were reduced.
Side Effect Rates
According to research published in JAMA Network Open, about 48.6% of semaglutide users report experiencing at least one adverse effect.
| Side Effect | Percentage of Users |
|---|---|
| Nausea | 37% (most common) |
| Diarrhea | 8.6% |
| Fatigue | 6.3% |
| Constipation | 5.7% |
| Stomach paralysis (gastroparesis) | 1% |
| Pancreatitis | 0.5% |
Most side effects are gastrointestinal and tend to decrease over time as the body adjusts to the medication.
Public Awareness and Opinion
GLP-1 medications have become a major topic of public discussion. Awareness has grown significantly over the past year.
According to KFF, 32% of adults have heard “a lot” about GLP-1 medications, up from just 19% in July 2023. Overall, 82% of Americans have heard at least a little about these drugs.
Medicare Coverage Opinion
The question of whether Medicare should cover GLP-1s for weight loss has broad public support:
- 61% of Americans think Medicare should cover GLP-1s for weight loss
- 66% of Democrats support coverage
- 55% of Republicans support coverage
- 71% of previous GLP-1 users support coverage
This bipartisan support suggests potential policy changes could expand access to these medications in the future.
Impact on Health and Lifestyle
GLP-1 medications appear to be having broader effects beyond individual health. According to Gallup data from October 2026, these drugs may be making a measurable dent in US obesity rates.
Users report significant lifestyle changes:
- 61% stopped other weight loss medications
- 60% stopped using personal trainers
- 55% stopped weight loss programs
- 56% report making healthier food choices
- 47% eat smaller portions
- 30% exercise more
- 33% of heavy drinkers reduced alcohol consumption
Body image has also improved, with 61% of users reporting positive feelings about their body compared to 46% before starting treatment.
Context: Obesity and Diabetes in America
To understand why so many Americans are turning to Ozempic, it helps to look at the broader health landscape.
Approximately 42% of American adults have obesity (BMI 30+), and an additional 30%+ are overweight. This means more than 70% of American adults could potentially benefit from weight management interventions.
For type 2 diabetes, 36 million Americans (10% of the population) have been diagnosed. Type 2 accounts for 90-95% of all diabetes cases.
In 2026, there are signs that obesity rates may be declining for the first time in years, potentially influenced by increased GLP-1 usage.
Frequently Asked Questions
How many people are on Ozempic in the USA?
About 1 in 8 American adults (12%) have used a GLP-1 medication like Ozempic, with 6% currently taking one. Specifically for Ozempic, approximately 2% of American adults were prescribed the medication in 2024, making it the most popular GLP-1 drug in the United States. This translates to roughly 15-16 million current GLP-1 users overall.
How many people are on Ozempic in 2025?
As of 2025, approximately 12.4% of American adults report taking GLP-1 drugs like Ozempic, according to Gallup polling. This represents a significant increase from 5.8% in February 2024, showing that usage has more than doubled in less than a year. The number continues to grow as these medications become more widely available.
How many Americans are on GLP-1 medications?
Approximately 6% of American adults are currently taking a GLP-1 medication, while 12% have ever tried one. This includes drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. Usage is projected to reach 30 million Americans, or 9% of the population, by 2030.
What percentage of people feel sick on Ozempic?
About 48.6% of semaglutide users report experiencing at least one side effect. Nausea is the most common, affecting approximately 37% of users. Other common side effects include diarrhea (8.6%), fatigue (6.3%), and constipation (5.7%). Most side effects are temporary and tend to decrease over time as the body adjusts to the medication.
Are people on Ozempic for life?
Most people do not stay on Ozempic long-term. Studies show that 66-75% of people stop taking GLP-1 medications within one year. The main reasons for discontinuation include cost (65%), side effects (39%), and supply shortages (28%). However, 42% of former users say they would resume treatment if cost and side effects were reduced.
How many people are taking Ozempic for weight loss?
About 38% of GLP-1 users take medications like Ozempic solely for weight loss. Another 23% use them for both weight loss and treating chronic conditions like diabetes. Younger adults (18-29) are most likely to use these drugs for weight loss only at 7%, while adults 65 and older rarely use them for weight loss alone at just 1%, largely due to Medicare coverage limitations.
The Bottom Line on Ozempic Usage in America
The data paints a clear picture: Ozempic and other GLP-1 medications have become a significant part of American healthcare in 2026. With 12% of adults having tried these drugs and usage continuing to grow, we’re witnessing one of the fastest medication adoption rates in recent history.
Key takeaways from the statistics include:
- Approximately 15-16 million Americans are currently using GLP-1 medications
- Usage has more than doubled since early 2024
- Cost remains the biggest barrier, with US prices up to 10 times higher than other countries
- Most users (66-75%) stop within the first year, primarily due to cost and side effects
- The market is projected to continue growing, potentially reaching 30 million users by 2030
As these medications continue to evolve and potentially become more affordable, we may see even greater adoption rates in the coming years.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Ozempic is a prescription medication approved by the FDA for type 2 diabetes treatment. Using it for weight loss without a prescription or medical supervision may be dangerous. Always consult a licensed healthcare provider before starting any medication, including GLP-1 drugs like Ozempic.
Sources: KFF Health Tracking Poll (May 2024), Gallup (October 2025), CDC/NCHS, SingleCare, NutritionNC, MIT Technology Review, Health System Tracker, JAMA Network Open, Outsourcing Facilities Association, Pew Research Center.